Provided by Tiger Trade Technology Pte. Ltd.

Lyell Immunopharma, Inc.

11.96
-0.2400-1.97%
Post-market: 11.960.00000.00%19:30 EDT
Volume:152.20K
Turnover:1.82M
Market Cap:293.07M
PE:-1.01
High:13.00
Open:12.41
Low:11.70
Close:12.20
52wk High:45.00
52wk Low:11.47
Shares:24.50M
Float Shares:10.79M
Volume Ratio:1.77
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.8281
EPS(LYR):-16.0562
ROE:-93.28%
ROA:-34.18%
PB:1.25
PE(LYR):-0.74

Loading ...

Lyell Immunopharma initiated with a Buy at B. Riley

TIPRANKS
·
Jul 22

Innovative Cellular Therapeutics Holdings Reports Lyell Immunopharma Share Sale Worth $137

Reuters
·
Jul 21

Innovative Cellular Therapeutics Holdings Reports Lyell Immunopharma Common Share Disposal Worth $137.3

Reuters
·
Jul 18

Lyell Immunopharma Files for Secondary Offering of Common Shares

MT Newswires Live
·
Jul 14

Lyell Immunopharma files to sell 1.1M shares of common stock for holders

TIPRANKS
·
Jul 14

Lyell Immunopharma - to Offer up to 1.1 Mln Common Shares by Selling Stockholder - SEC Filing

THOMSON REUTERS
·
Jul 14

Citizens biotech analyst holds an analyst/industry conference call

TIPRANKS
·
Jul 07

Abcellera Appoints Lyell CEO Lynn Seely to Board as Independent Director

Reuters
·
Jul 06

Citizens biotech analysts hold an analyst/industry conference call

TIPRANKS
·
Jul 03

Lyell Immunopharma to Join H.C. Wainwright Cell Therapy Virtual Conference Fireside Chat

Reuters
·
Jun 25

Lyell Immunopharma initial beneficial ownership filing names Innovative Cellular Therapeutics Holdings as 10% owner

Reuters
·
Jun 19

Lyell Immunopharma Shareholders Back Governance at 2026 Meeting

TIPRANKS
·
Jun 16

Lyell Immunopharma shareholders approved auditor Ernst & Young for 2026 fiscal year

Reuters
·
Jun 16

Lyell Immunopharma Price Target Maintained With a $44.00/Share by Needham

Dow Jones
·
Jun 15

BRIEF-Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma

Reuters
·
Jun 13

Lyell Immunopharma - Pinacle Pivotal Trial Data Update Expected H2 2026; Bla Submission Planned H2 2027

THOMSON REUTERS
·
Jun 13

Lyell Immunopharma - Ronde-Cel Treated Over 100 Patients in 2L and 3L+ Lbcl With 97% Manufacturing Success Rate

THOMSON REUTERS
·
Jun 13

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients With Large B-Cell Lymphoma at European Hematology Association 2026 Congress

THOMSON REUTERS
·
Jun 13

Lyell Immunopharma - No Grade 3 or Higher Crs and Low Rates of Grade 3 or Higher Icans Reported

THOMSON REUTERS
·
Jun 13

Lyell Immunopharma says ronde-cel Phase 1/2 study in LBCL shows no grade 3+ CRS

Reuters
·
Jun 13